Clinical Trial

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

Study acronym: AETHER
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
In this study, efficacy and safety of 2 regimens that combine the CD3-CD20 T cell engager epcoritamab with venetoclax will be tested in relapsed/refractory CLL and SLL patients. The trial starts with phase I part to establish the recommended dose level (RDL) of epcoritamab in the combination with venetoclax for the phase II trial.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-03-28.
Status change: Not Yet Recruiting → Recruiting 2024-04-10
Trial Details
NCT Number NCT05791409
Lead Sponsor Stichting Hemato-Oncologie voor Volwassenen Nederland
Collaborators: Nordic CLL Study Group, German CLL Study Group
Conditions CLL/SLL
Enrollment 112 participants
Start Date 2024-04-10
Primary Completion 2029-03 (estimated)
Study Completion 2032-11 (estimated)
Updated on ClinicalTrials.gov 2024-04-12